Andrea Antinori
Overview
Explore the profile of Andrea Antinori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
518
Citations
8963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pesonel E, Laouenan C, Guiraud L, Bourner J, Hoffmann I, Molino D, et al.
Clin Infect Dis
. 2025 Jan;
PMID: 39749987
Background: The global mpox outbreak which started in May 2022 was caused by a novel clade IIb variant of the mpox virus (MPXV). It differed from the traditional Western and...
12.
Camici M, Del Duca G, Brita A, Antinori A
Front Cell Infect Microbiol
. 2024 Dec;
14:1501949.
PMID: 39735263
The pathogenesis of long COVID (LC) still presents many areas of uncertainty. This leads to difficulties in finding an effective specific therapy. We hypothesize that the key to LC pathogenesis...
13.
Tan D, Antinori A, Eu B, Galindo Puerto M, Kinder C, Sweet D, et al.
J Acquir Immune Defic Syndr
. 2024 Dec;
98(4):401-409.
PMID: 39676239
Background: Modest weight and lipid changes have been observed in cabotegravir plus rilpivirine long-acting (CAB + RPV LA) phase 3/3b studies. The SOLAR study included standardized evaluations of weight and...
14.
Monforte A, Tavelli A, Quiros-Roldan E, Fabbiani M, Ferrara M, Caputo S, et al.
HIV Med
. 2024 Dec;
26(3):489-499.
PMID: 39618291
Rationale: Doravirine (DOR) is an attractive new option both for ART-naïve people with HIV (PWH) and those with suppressed HIV-RNA who seek treatment simplification. We used real-world data to examine...
15.
Mastrorosa I, Lepri A, Borgo C, Rosati S, Rueca M, Sarmati L, et al.
J Intern Med
. 2024 Nov;
297(3):328-334.
PMID: 39537383
Objectives: To estimate the risk of COVID-19-related hospitalization and death (CovH/D), among high-risk individuals early treated for COVID-19 and to identify associated factors. Methods And Results: A multicenter cohort of...
16.
Bordi L, DAuria A, Frasca F, Mazzotta V, Mazzetti P, Fracella M, et al.
Med Microbiol Immunol
. 2024 Nov;
213(1):25.
PMID: 39527317
The recent outbreak of monkeypox virus (MPXV) has caused global concern. How the virus evades the interferon (IFN) response is still poorly understood. We analyzed type I/II IFN (IFN-I/II) expression...
17.
Vergori A, Del Duca G, Borrelli P, Brita A, Pinnetti C, Mastrorosa I, et al.
Heliyon
. 2024 Oct;
10(20):e39431.
PMID: 39469684
Background: We aim to investigate the proportion of patients (pts) with long-term cognitive outcomes (CO) of PACC and identify associated features. Methods: We assessed participants through a neuropsychological assessment. The...
18.
Vergori A, Del Duca G, Lorenzini P, Brita A, Mastrorosa I, Fusto M, et al.
AIDS
. 2024 Oct;
39(3):270-275.
PMID: 39453875
Objectives: The aim was to investigate whether switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/F/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) may improve neuropsychiatric symptoms and neurocognition. Design: Pilot, single-arm, prospective study of persons...
19.
Pinnetti C, Rozera G, Messina F, Spezia P, Lazzari E, Fabeni L, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408789
Signatures of neurodegeneration in clinical samples from a subject with multiple sclerosis (MS) acutely infected with HIV were investigated with single-cell transcriptomics using 10X Chromium technology. Sequencing was carried out...
20.
Matusali G, Cimini E, Mazzotta V, Colavita F, Maggi F, Antinori A
J Infect
. 2024 Oct;
89(6):106309.
PMID: 39368640
No abstract available.